专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08883168B2 Modulation of immune responses by the poxviral K4 protein 有权
标题翻译：由痘病毒K4蛋白调节免疫反应
公开(公告)号：US08883168B2
公开(公告)日：2014-11-11
申请号：US13883529
申请日：2011-11-07
申请人： Jürgen Hausmann , Hubertus Hochrein , Christine Meisinger-Henschel
发明人： Jürgen Hausmann , Hubertus Hochrein , Christine Meisinger-Henschel
IPC分类号： A61K39/275 , A61K39/285 , C12N7/00 , C12N7/01 , C12N15/863 , G01N33/50 , C07K14/005 , C12N15/86 , C12N15/113 , A61K39/39 , A61K39/00
CPC分类号： C12N7/00 , A61K39/285 , A61K39/39 , A61K2039/5256 , C07K14/005 , C12N15/1131 , C12N15/86 , C12N2310/14 , C12N2710/24122 , C12N2710/24132 , C12N2710/24134 , C12N2710/24143 , C12N2710/24171 , G01N33/5008
摘要： The present invention relates to compositions, methods, and uses involving the modulation of K4 protein activity, especially in the treatment of various diseases and in the enhancement of vaccination regimens. The invention relates to poxviruses having reduced or increased K4 protein activity, as well as methods of making and using these poxviruses. The invention further relates to K4 proteins and inhibitors of K4 protein activity, as well as methods for making and using them.
摘要翻译：本发明涉及涉及调节K4蛋白活性的组合物，方法和用途，特别是在治疗各种疾病和增强疫苗接种方案中。本发明涉及具有降低或增加的K4蛋白活性的痘病毒，以及制备和使用这些痘病毒的方法。本发明还涉及K4蛋白和K4蛋白活性的抑制剂，以及制备和使用它们的方法。

2. 发明申请

US20080317778A1 MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD 有权
标题翻译：改良的VACCINIA安卡拉病毒变种和培养方法
公开(公告)号：US20080317778A1
公开(公告)日：2008-12-25
申请号：US12200176
申请日：2008-08-28
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
IPC分类号： A61K39/12 , C12N7/02
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译：本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

3. 发明授权

US07459270B2 Modified Vaccinia Ankara virus variant 有权
公开(公告)号：US07459270B2
公开(公告)日：2008-12-02
申请号：US11999127
申请日：2007-12-04
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel
IPC分类号： C12Q1/70 , C12N5/10 , C12N15/863 , A61K39/275 , A61K39/285 , A61K48/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen.

4. 发明授权

US07445924B2 Modified Vaccinia Ankara virus variant and cultivation method 有权
标题翻译：改良牛痘安卡拉病毒变种及培养方法
公开(公告)号：US07445924B2
公开(公告)日：2008-11-04
申请号：US11071741
申请日：2005-03-03
申请人： Paul Chaplin , Paul Howley , Christine Meisinger , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger , Ingmar Rathe , Eva Felder , Karl Heller
IPC分类号： C12N7/02 , A61K39/285 , A61K39/02
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译：本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。此外，提供了一种用于在痘苗病毒原/痘苗病毒增强接种方案中施用治疗有效量的病毒或其重组体的方法。本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

5. 发明授权

US07384644B2 Modified Vaccinia Ankara virus variant 有权
标题翻译：改良牛痘安卡拉病毒变体
公开(公告)号：US07384644B2
公开(公告)日：2008-06-10
申请号：US11198557
申请日：2005-08-05
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel
IPC分类号： A61K39/00 , A61K39/275 , C12N7/08 , A61K39/23
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or a derivative thereof, required to confer said immunity is less than the effective amount of MVA-575 required to render said mouse immune to a lethal vaccinia virus infection, and/or the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
摘要翻译：本发明提供一种减毒病毒，其来源于改良牛痘安卡拉病毒，其特征在于在小鼠中诱导针对致死性痘苗病毒感染的保护性免疫力，由此需要有效量的MVA-BN病毒或其衍生物赋予所述免疫力小于使所述小鼠免疫致死性痘苗病毒感染所需的MVA-575的有效量，和/或MVA-BN病毒或其衍生物诱导至少基本上相同的免疫水平与DNA痘苗/痘苗病毒增强方案相比，在痘苗病毒原始/疫苗病毒增强方案中。它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。

6. 发明授权

US06913752B2 Modified Vaccinia Ankara virus variant 有权
标题翻译：改良牛痘安卡拉病毒变体
公开(公告)号：US06913752B2
公开(公告)日：2005-07-05
申请号：US10439439
申请日：2003-05-16
申请人： Paul Chaplin , Paul Howley , Christine Meisinger
发明人： Paul Chaplin , Paul Howley , Christine Meisinger
IPC分类号： C12N15/09 , A61K39/275 , A61K39/285 , A61K39/39 , A61K48/00 , A61P37/04 , C07K14/16 , C12N5/10 , C12N7/00 , C12N7/01 , C12N7/02 , C12N7/04 , C12N15/39 , C12N15/863 , C12P21/02 , C12R1/93 , A61K39/295
CPC分类号： C07K14/005 , A61K39/12 , A61K39/285 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/24121 , C12N2710/24143 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
摘要翻译：本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。此外，提供了一种用于在痘苗病毒原/痘苗病毒增强接种方案中施用治疗有效量的病毒或其重组体的方法。

7. 发明申请

US20110217757A1 MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD 有权
标题翻译：改良的VACCINIA安卡拉病毒变种和培养方法
公开(公告)号：US20110217757A1
公开(公告)日：2011-09-08
申请号：US13106176
申请日：2011-05-12
申请人： PAUL CHAPLIN , PAUL HOWLEY , CHRISTINE MEISINGER-HENSCHEL , INGMAR RATHE , EVA FELDER , KARL HELLER
发明人： PAUL CHAPLIN , PAUL HOWLEY , CHRISTINE MEISINGER-HENSCHEL , INGMAR RATHE , EVA FELDER , KARL HELLER
IPC分类号： C12N7/02
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译：本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

8. 发明授权

US07964395B2 Modified vaccinia ankara virus variant and cultivation method 有权
标题翻译：改良痘苗病毒变种和培养方法
公开(公告)号：US07964395B2
公开(公告)日：2011-06-21
申请号：US12200176
申请日：2008-08-28
申请人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
发明人： Paul Chaplin , Paul Howley , Christine Meisinger-Henschel , Ingmar Rathe , Eva Felder , Karl Heller
IPC分类号： A01N63/00 , A61K39/00 , A61K39/275 , A61K45/00 , C12N5/07 , C12N7/00 , C12N7/02 , C12N5/00 , C12P1/00 , C12P21/04 , A61K39/165
CPC分类号： A61K39/285 , A61K39/12 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , C07K14/005 , C12N7/00 , C12N15/86 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2740/16322
摘要： The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
摘要翻译：本发明提供一种减毒病毒，其衍生自改良的痘苗安卡拉病毒，其特征在于丧失其在人细胞系中繁殖复制的能力。它还描述了源自该病毒的重组病毒和病毒或其重组体作为药物或疫苗的用途。提供了一种方法，用于在可能被免疫损害的个体中诱导免疫应答，接受抗病毒治疗或具有疫苗病毒的预先存在的免疫。此外，提供了一种用于在痘苗病毒原/痘苗病毒加强接种方案中施用治疗有效量的病毒或其重组体的方法。本发明涉及在无血清培养基中培养的原代细胞中的病毒扩增方法。通过该方法产生的病毒有利地不含动物血清中包含的任何传染性物质。

9. 发明申请

US20090162935A1 VACCINIA VIRUS HOST RANGE GENES TO INCREASE THE TITER OF AVIPOXVIRUSES 审中-公开
标题翻译： VACCINIA病毒宿主区域增加AVIPOXVIRUSES的标准
公开(公告)号：US20090162935A1
公开(公告)日：2009-06-25
申请号：US12198220
申请日：2008-08-26
申请人： Paul Howley , Christine Meisinger-Hensdel
发明人： Paul Howley , Christine Meisinger-Hensdel
IPC分类号： C12N15/87 , C12N7/00
CPC分类号： C12N15/86 , A61K35/00 , A61K48/00 , A61K2039/525 , C07K14/005 , C12N2710/24122 , C12N2710/24143 , C12N2830/00 , C12N2830/15 , C12N2830/60 , C12N2840/203
摘要： The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover, the invention concerns the use of a Vaccinia virus host range gene or a homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus, wherein the host range gene is expressed in the cells.
摘要翻译：本发明涉及一种在病毒基因组中包含痘苗病毒宿主范围基因或所述宿主范围基因的同系物的禽病毒。本发明还涉及包含牛痘病毒宿主范围基因或所述宿主范围基因的同系物的细胞，优选禽类细胞。此外，本发明涉及使用痘苗病毒宿主范围基因或其同源物来增加所述细胞在用所述禽病毒感染后由细胞产生的avipoxvirirus的滴度，其中宿主范围基因在细胞中表达。

10. 发明授权

US07473536B2 Isolated avian cell that expresses Vaccinia virus host range genes 失效
标题翻译：分离的禽类细胞表达痘苗病毒宿主范围基因
公开(公告)号：US07473536B2
公开(公告)日：2009-01-06
申请号：US10524043
申请日：2003-07-29
申请人： Paul Howley , Christine Meisinger-Henschel
发明人： Paul Howley , Christine Meisinger-Henschel
IPC分类号： A61K39/12 , A61K39/275 , C12P1/00 , C12P21/06 , C12P21/04 , A61K39/00
CPC分类号： C12N15/86 , A61K35/00 , A61K48/00 , A61K2039/525 , C07K14/005 , C12N2710/24122 , C12N2710/24143 , C12N2830/00 , C12N2830/15 , C12N2830/60 , C12N2840/203
摘要： The invention concerns an Avipoxvirus comprising in the viral genome a Vaccinia virus host range gene or a homologue of said host range gene. The invention further relates to cells, preferably avian cells, comprising a Vaccinia virus host range gene or a homologue of said host range gene. Moreover the invention concerns the use of a Vaccinia virus host range gene or an homologue thereof to increase the titer of avipoxviruses produced from cells after infection of said cells with the avipoxvirus, wherein the host range gene is expressed in said cells.
摘要翻译：本发明涉及一种在病毒基因组中包含痘苗病毒宿主范围基因或所述宿主范围基因的同系物的禽病毒。本发明还涉及包含牛痘病毒宿主范围基因或所述宿主范围基因的同系物的细胞，优选禽类细胞。此外，本发明涉及使用痘苗病毒宿主范围基因或其同源物来增加所述细胞在用所述禽病毒感染后由细胞产生的avipoxvirus的滴度，其中所述宿主范围基因在所述细胞中表达。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式